Gene Techno CEO Eyes Lucentis Biosimilar Launch in November 2021, Expects Share of “At Least 30%”

April 23, 2020
Gene Techno Science plans to file what could be Japan’s first Lucentis (ranibizumab) biosimilar as early as September, aiming for its approval a year later and its listing and launch in November 2021, President and CEO Masaharu Tani said in...read more